Nelde, Annika http://orcid.org/0000-0001-8504-8481
Flötotto, Lea
Jürgens, Lara
Szymik, Laura
Hubert, Elvira
Bauer, Jens http://orcid.org/0000-0003-3731-2385
Schliemann, Christoph
Kessler, Torsten
Lenz, Georg
Rammensee, Hans-Georg
Walz, Juliane S. http://orcid.org/0000-0001-6404-7391
Wethmar, Klaus
Funding for this research was provided by:
Deutsche Krebshilfe (70113632)
Eurostars-2 (E!11969 compare)
`Clinician Scientist Program´ of the Deanery of the Medical Faculty of the University of Münster
`MedK Program´ of the Deanery of the Medical Faculty of the University of Münster
Deutsche Forschungsgemeinschaft (WA 4608/1-2)
Deutsche Forschungsgemeinschaft under Germany’s Excellence Strategy (EXC2180 390900677, EXC2180 390900677)
German Cancer Consortium
Wilhelm Sander-Stiftung (2016.177.2, 2016.177.3)
José Carreras Leukämie-Stiftung (DJCLS 05 R/2017)
Fortüne Program of the University of Tübingen (2451-0-0)
Eberhard Karls Universität Tübingen
Article History
Received: 7 October 2021
Revised: 21 December 2021
Accepted: 10 January 2022
First Online: 3 March 2022
Declarations
:
: H.-G.R. is shareholder of Immatics Biotechnologies GmbH, Synimmune GmbH, and Curevac AG. The other authors declare no competing interests.
: Informed consent was obtained in accordance with the Declaration of Helsinki protocol. The study was performed according to the guidelines of the local ethics committees (373/2011B02, 454/2016B02, 406/2019B02).
: Not applicable.